Homo sapiens Protein: ATXN2 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Summary | |||||||||||||||||||||||||
InnateDB Protein | IDBP-57481.6 | ||||||||||||||||||||||||
Last Modified | 2014-10-13 [Report errors or provide feedback] | ||||||||||||||||||||||||
Gene Symbol | ATXN2 | ||||||||||||||||||||||||
Protein Name | ataxin 2 | ||||||||||||||||||||||||
Synonyms | ASL13; ATX2; SCA2; TNRC13; | ||||||||||||||||||||||||
Species | Homo sapiens | ||||||||||||||||||||||||
Ensembl Protein | ENSP00000366843 | ||||||||||||||||||||||||
InnateDB Gene | IDBG-57479 (ATXN2) | ||||||||||||||||||||||||
Protein Structure | |||||||||||||||||||||||||
UniProt Annotation | |||||||||||||||||||||||||
Function | Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane. {ECO:0000269PubMed:18602463}. | ||||||||||||||||||||||||
Subcellular Localization | Cytoplasm {ECO:0000250}. | ||||||||||||||||||||||||
Disease Associations | Spinocerebellar ataxia 2 (SCA2) [MIM:183090]: Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is characterized by hyporeflexia, myoclonus and action tremor and dopamine-responsive parkinsonism. In some patients, SCA2 presents as pure familial parkinsonism without cerebellar signs. {ECO:0000269PubMed:8896555, ECO:0000269PubMed:8896556, ECO:0000269PubMed:8896557}. Note=The disease is caused by mutations affecting the gene represented in this entry. SCA2 is caused by expansion of a CAG repeat resulting in about 36 to 52 repeats in some patients. Longer expansions result in earlier the expansion, onset of the disease.Amyotrophic lateral sclerosis 13 (ALS13) [MIM:183090]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5- 10% of the cases. {ECO:0000269PubMed:20740007}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. An increased risk for developing amyotrophic lateral sclerosis seems to be conferred by CAG repeat intermediate expansions greater than 23 but below the threshold for developing spinocerebellar ataxia. | ||||||||||||||||||||||||
Tissue Specificity | Expressed in the brain, heart, liver, skeletal muscle, pancreas and placenta. Isoform 1 is predominant in the brain and spinal cord. Isoform 4 is more abundant in the cerebellum. In the brain, broadly expressed in the amygdala, caudate nucleus, corpus callosum, hippocampus, hypothalamus, substantia nigra, subthalamic nucleus and thalamus. {ECO:0000269PubMed:8896555, ECO:0000269PubMed:8896556, ECO:0000269PubMed:8896557, ECO:0000269PubMed:9480749}. | ||||||||||||||||||||||||
Comments | |||||||||||||||||||||||||
Interactions | |||||||||||||||||||||||||
Number of Interactions |
This gene and/or its encoded proteins are associated with 50 experimentally validated interaction(s) in this database.
They are also associated with 4 interaction(s) predicted by orthology.
|
||||||||||||||||||||||||
Gene Ontology | |||||||||||||||||||||||||
Molecular Function |
|
||||||||||||||||||||||||
Biological Process |
|
||||||||||||||||||||||||
Cellular Component |
|
||||||||||||||||||||||||
Protein Structure and Domains | |||||||||||||||||||||||||
PDB ID | |||||||||||||||||||||||||
InterPro |
IPR009604
LsmAD domain IPR009818 Ataxin-2, C-terminal IPR010920 Like-Sm (LSM) domain |
||||||||||||||||||||||||
PFAM |
PF06741
PF07145 |
||||||||||||||||||||||||
PRINTS | |||||||||||||||||||||||||
PIRSF | |||||||||||||||||||||||||
SMART | |||||||||||||||||||||||||
TIGRFAMs | |||||||||||||||||||||||||
Post-translational Modifications | |||||||||||||||||||||||||
Modification | |||||||||||||||||||||||||
Cross-References | |||||||||||||||||||||||||
SwissProt | Q99700 | ||||||||||||||||||||||||
PhosphoSite | PhosphoSite-Q99700 | ||||||||||||||||||||||||
TrEMBL | V9GY86 | ||||||||||||||||||||||||
UniProt Splice Variant | |||||||||||||||||||||||||
Entrez Gene | 6311 | ||||||||||||||||||||||||
UniGene | Hs.76253 | ||||||||||||||||||||||||
RefSeq | NP_002964 | ||||||||||||||||||||||||
HUGO | HGNC:10555 | ||||||||||||||||||||||||
OMIM | 601517 | ||||||||||||||||||||||||
CCDS | CCDS31902 | ||||||||||||||||||||||||
HPRD | 03307 | ||||||||||||||||||||||||
IMGT | |||||||||||||||||||||||||
EMBL | AC002395 AC137055 AK128613 EU796974 EU796975 EU796976 EU796977 U70323 Y08262 | ||||||||||||||||||||||||
GenPept | AAB19200 ACJ05009 ACJ05010 ACJ05011 ACJ05012 BAC87528 CAA69589 | ||||||||||||||||||||||||